Updated continuously, all day

Stay current with the people and research shaping what comes next.

PeerCurrent turns the flood of scientific knowledge into a personalized, intelligent feed: summarized, organized and discussed by researchers, clinicians and industry professionals. Launching in life sciences, it helps you follow the diseases, therapies, companies, trials, publications and experts that matter to your work.

Evidence-graded, never one opaque score Source-linked, every claim 7 days free, no card to start
Your briefing · Today

Good morning, Dr. Adam.

For you · Cardiology
New England Journal of Medicine · RCT · Today
Potentially Practice-Changing
Earlier anticoagulation after stroke lowers recurrence without excess bleeding

Why it matters. Large randomized data may move the timing of a decision you make weekly.

The Lancet · Meta-analysis · Today
Strong Evidence
GLP-1 therapy and cardiovascular outcomes: pooled results across 9 trials

Why it matters. Consistent effect strengthens a growing prescribing case.

FDA · Safety · Today
Regulatory Update
Updated label warning for a widely used antibiotic class
Briefing Search Saved You
The problem is not access. It is time.

Thousands of papers publish daily. A handful should change your practice.

PeerCurrent does the reading and the judging, so your attention goes only where it counts.

01

What changed

The developments in your specialty since you last looked, pulled from journals, trials, guidelines, agencies, and preprints.

02

Why it matters to you

Plain-language context tied to your role and the topics you follow, so relevance is obvious in seconds.

03

How strong the evidence is

A transparent, multidimensional read of the evidence, graded from the source, so you can trust it or challenge it.

A briefing you flip through

Today, in your field. Swipe.

One development per card. Swipe to move on, tap to open the full analysis and its source. This is the real feel of the mobile app.

New England Journal of Medicine · Randomized Controlled Trial
Potentially Practice-Changing

Earlier anticoagulation after ischemic stroke reduces recurrence

Why it matters. Randomized evidence on timing, directly relevant to an acute decision, with a favorable bleeding profile.

Study design
Directness
Consistency
Risk of bias
The Lancet · Meta-analysis
Strong Evidence

GLP-1 receptor agonists and major cardiovascular events

Why it matters. Pooled across nine trials, the direction and size of effect are consistent.

Study design
Consistency
Directness
Sample adequacy
JAMA · Cohort study
Promising

Continuous glucose monitoring linked to fewer admissions in type 2 diabetes

Why it matters. Observational, so promising rather than definitive, but a signal worth watching.

Study design
Directness
Risk of bias
FDA · Drug safety communication
Regulatory Update

Updated boxed warning for a common antibiotic class

Why it matters. Prescribing guidance you should know before your next script.

Source
Directness
Swipe or use the arrows
Trust before cleverness

An expert's read of the evidence, not a mystery score.

Every development is assessed across the dimensions that decide whether you should act, each graded only from what the source actually supports, and never invented.

Evidence assessment

Earlier anticoagulation after ischemic stroke

Study designstrongMulticenter randomized controlled trial
DirectnessstrongPopulation matches everyday practice
ConsistencymoderateAligns with prior smaller trials
Risk of biasmoderateOpen-label outcome adjudication
Sample adequacystrongPowered for the primary endpoint

The bottom line, in one read.

What changed, the numbers that matter, how strong it is, what it changes in practice, and the caveat. Written the way a trusted colleague would summarize it to you, then linked straight to the paper so you can verify in one tap.

No fabricated statistics. No single opaque rating. When the evidence does not support a firm read, it says so.

Ninety seconds to set up

How it works

Tell it your field

Pick your specialty and the topics you track. Your briefing is ranked for you from the first morning.

Read your briefing

Each morning, the developments that matter, graded and explained, with the noise already filtered out.

Act with confidence

Open the full analysis, check the source, save it, or share your read with colleagues. All in a few taps.

Built for clinicians first

Made for the bedside. Growing with you.

PeerCurrent starts with practicing clinicians, and the same engine extends to the people who work alongside the evidence.

Available now

Clinicians

Stay current in your specialty without the doomscroll. Know what changed and whether it changes your management.

Coming next

Researchers & scientists

Track your field across journals and preprints, connect findings, and never miss a result that touches your work.On the roadmap

Coming next

Life-science investors

Follow the research, trial readouts, and regulatory actions behind the companies you watch. Information, not advice.On the roadmap

Start free

One week free. Then pick your pace.

Full access for 7 days. Keep it if it earns a place in your morning.

Monthly
$29 / month
Billed monthly. Cancel anytime.
  • Your personalized daily briefing
  • Multidimensional evidence grading
  • Search, save, and export
  • Follow topics, journals, and agencies
Start free week
Best value
Annual
$290 / year
About $24 per month. Two months free.
  • Everything in Monthly
  • Priority access to new features
  • Early access to the investor and research views
  • Your public intelligence profile
Start free week
Teams & institutions
Let's talk
Departments, groups, and organizations.
  • Seats for your whole team
  • Shared collections and curation
  • Onboarding and admin controls
  • Volume pricing
Contact us
Good to know

Questions, answered

Where does the information come from?+

Peer-reviewed journals, clinical trial registries, guidelines, regulatory agencies, and preprints. Every item links to its original source so you can read it yourself in one tap.

How does the evidence grading work?+

Each development is assessed across dimensions like study design, directness, consistency, risk of bias, and sample adequacy, graded only from what the source supports. You always see the reasoning, never a single mystery score, and it says so plainly when the evidence is thin.

Is it personalized to my specialty?+

Yes. You choose your field and the topics, journals, and agencies you follow, and your briefing is ranked for you, with a short note on why each item is in front of you.

Does the free trial need a credit card?+

You get 7 days of full access to decide if it earns a place in your morning. Keep it with a monthly or annual plan when you are ready.

Is this medical advice?+

No. PeerCurrent surfaces and summarizes evidence to support your judgment. Clinical decisions remain yours, and you should always confirm against the original source before acting.

Discover faster. Understand deeper. Join the conversation.

Give PeerCurrent one week. If your first briefing does not save you time and sharpen your read of the evidence, walk away.

Start your free week